<p>随着全球市场应对贸易政策和通胀趋势的复杂性，投资者密切关注这些因素对股票表现的影响。美国股票在关税不确定性中表现出韧性，而欧洲指数因通胀预期缓解而受到提振，股息股票继续成为那些寻求在波动市场环境中获得稳定收入的投资者的吸引选项。</p>
<h3>全球十大股息股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股息收益率</strong></td>
<td><strong>股息评级</strong></td>
</tr>
<tr>
<td>en-japan (TSE:4849)</td>
<td>4.28%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大东信托建设有限公司 (TSE:1878)</td>
<td>4.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>安联 (XTRA:ALV)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大庆化学 (TSE:4202)</td>
<td>4.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CAC 控股 (TSE:4725)</td>
<td>4.88%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>山田工业 (TSE:5444)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>同志社有限公司 (TSE:7483)</td>
<td>4.36%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>学究社有限公司 (TSE:9769)</td>
<td>4.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>沃州银行 (SWX:BCVN)</td>
<td>4.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>日本优秀 (TSE:8987)</td>
<td>4.40%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们全球十大股息股票筛选器的 1552 只股票的完整列表。</p>
<p>我们将查看筛选工具中一些最佳选择。</p>
<h2>ORION 控股 (KOSE:A001800)</h2>
<p><strong>Simply Wall St 股息评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> ORION 控股公司是一家在韩国、中国及国际上制造和销售糖果的公司，市值为₩1.12 万亿。</p>
<p><strong>运营：</strong> ORION 控股公司的收入部分包括糖果业务₩3.90 万亿，房东业务₩66.56 亿，以及视频业务₩41.64 亿。</p>
<p><strong>股息收益率：</strong> 3.6%</p>
<p>ORION 控股的股息支付得到了收益和现金流的良好支持，派息比率为 31.5%，现金派息比率为 12.6%。然而，过去十年股息波动较大，尽管在此期间支付有所增长，但显示出不可靠性。最近的财报显示业绩波动，2025 年第一季度净收入较去年下降，突显出维持稳定股息的潜在挑战。</p>
<ul>
<li>点击这里了解 ORION 控股的细微差别，查看我们的详细分析股息报告。</li>
<li>我们的估值报告显示 ORION 控股可能被低估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend"/></p>
<p>截至 2025 年 6 月的 KOSE:A001800 股息历史</p>
<h2>桂林三金药业 (SZSE:002275)</h2>
<p><strong>Simply Wall St 股息评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 桂林三金药业有限公司专注于中国传统中药和天然药物的研究、生产和销售，市值为 CN¥86.2 亿。</p>
<p><strong>运营：</strong> 桂林三金药业有限公司主要通过研究、生产和销售中国传统中药和天然药物来产生收入。</p>
<p><strong>股息收益率：</strong> 3.7%</p>
<p>桂林三金药业的股息得到了收益和现金流的良好支持，派息比率分别为 66.6% 和 67.9%。尽管在中国是顶级股息支付者之一，但其过去十年的记录不稳定，支付没有增长。最近批准的每 10 股派发 CNY 3.50 的股息突显了尽管过去波动和大额一次性项目影响财务结果，仍然致力于回报。</p>
<ul>
<li>通过我们的综合股息报告了解桂林三金药业的复杂性。</li>
<li>我们精心准备的桂林三金药业估值报告暗示其股价可能低于预期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend"/></p>
<p>截至 2025 年 6 月的 SZSE:002275 股息历史</p>
<h2>青岛百合医疗 (SZSE:301015)</h2>
<p><strong>Simply Wall St 股息评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 青岛百合医疗有限公司从事药品的研究、开发、生产和销售，市值为 CN¥98.4 亿。</p>
<p><strong>运营：</strong> 青岛百合医疗有限公司通过药品的研究、开发、生产和销售来产生收入。</p>
<p><strong>股息收益率：</strong> 3.8%</p>
<p>青岛百合医疗的股息支付得到了收益和现金流的良好支持，派息比率分别为 67.6% 和 68.2%。尽管该公司仅支付了三年的股息，但每 10 股派发 CNY 7.62 的股息反映了对股东的稳定承诺，使其成为中国顶级股息支付者之一。尽管最近的收益压力使 2025 年第一季度净收入下降至 CNY 8500 万，但由于强劲的覆盖指标，股息仍然可持续。</p>
<ul>
<li>点击探索我们在青岛百合医疗股息报告中的详细发现。</li>
<li>我们编制的估值报告表明青岛百合医疗的当前价格可能相当适中。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend"/></p>
<p>截至 2025 年 6 月的 SZSE:301015 股息历史</p>
<h2>将想法转化为行动</h2>
<ul>
<li>在这里浏览 1552 只全球顶级股息股票的完整清单。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取任何新警告信号的提醒。</li>
<li>Simply Wall St 是您解锁全球市场趋势的关键，是一款面向前瞻性投资者的免费用户友好应用。</li>
</ul>
<h2>准备好不同的方法了吗？</h2>
<ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，得到分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
<p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

桂林三金

Orion集团控股

<p>随着全球市场面临贸易政策复杂性和通胀趋势，股息股票因其稳定的收入而仍然具有吸引力。全球前十大股息股票包括 en-japan、大东信托建设、安联等，收益率范围从 4.04% 到 4.93%。像 ORION 集团控股和桂林三金这样的公司显示出强劲的股息覆盖率，但也经历了波动。青岛百合医疗尽管近期面临盈利压力，但仍保持可持续的股息。此分析强调了在波动市场中股息股票的重要性，为寻求可靠回报的投资者提供了见解</p>

<p>As global markets navigate the complexities of trade policies and inflation trends, investors are keenly observing the impact of these factors on equity performance. With U.S. stocks showing resilience amid tariff uncertainties and European indices buoyed by easing inflation expectations, dividend stocks continue to be an attractive option for those seeking steady income in a fluctuating market environment.</p>
<div class="lb-trans"><p>随着全球市场应对贸易政策和通胀趋势的复杂性，投资者密切关注这些因素对股票表现的影响。美国股票在关税不确定性中表现出韧性，而欧洲指数因通胀预期缓解而受到提振，股息股票继续成为那些寻求在波动市场环境中获得稳定收入的投资者的吸引选项。</p>
</div><h3>Top 10 Dividend Stocks Globally</h3>
<div class="lb-trans"><h3>全球十大股息股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Dividend Yield</strong></td>
<td><strong>Dividend Rating</strong></td>
</tr>
<tr>
<td>en-japan (TSE:4849)</td>
<td>4.28%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daito Trust ConstructionLtd (TSE:1878)</td>
<td>4.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Allianz (XTRA:ALV)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Daicel (TSE:4202)</td>
<td>4.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CAC Holdings (TSE:4725)</td>
<td>4.88%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Yamato Kogyo (TSE:5444)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>DoshishaLtd (TSE:7483)</td>
<td>4.36%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>GakkyushaLtd (TSE:9769)</td>
<td>4.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Banque Cantonale Vaudoise (SWX:BCVN)</td>
<td>4.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Japan Excellent (TSE:8987)</td>
<td>4.40%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股息收益率</strong></td>
<td><strong>股息评级</strong></td>
</tr>
<tr>
<td>en-japan (TSE:4849)</td>
<td>4.28%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大东信托建设有限公司 (TSE:1878)</td>
<td>4.42%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>安联 (XTRA:ALV)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>大庆化学 (TSE:4202)</td>
<td>4.93%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>CAC 控股 (TSE:4725)</td>
<td>4.88%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>山田工业 (TSE:5444)</td>
<td>4.39%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>同志社有限公司 (TSE:7483)</td>
<td>4.36%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>学究社有限公司 (TSE:9769)</td>
<td>4.04%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>沃州银行 (SWX:BCVN)</td>
<td>4.65%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>日本优秀 (TSE:8987)</td>
<td>4.40%</td>
<td>★★★★★★</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 1552 stocks from our Top Global Dividend Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们全球十大股息股票筛选器的 1552 只股票的完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我们将查看筛选工具中一些最佳选择。</p>
</div><h2>ORION Holdings (KOSE:A001800)</h2>
<div class="lb-trans"><h2>ORION 控股 (KOSE:A001800)</h2>
</div><p><strong>Simply Wall St Dividend Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 股息评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> ORION Holdings Corp. is a company that manufactures and sells confectioneries in South Korea, China, and internationally, with a market cap of ₩1.12 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> ORION 控股公司是一家在韩国、中国及国际上制造和销售糖果的公司，市值为₩1.12 万亿。</p>
</div><p><strong>Operations:</strong> ORION Holdings Corp.'s revenue segments include Confectionery at ₩3.90 trillion, Landlord at ₩66.56 billion, and Video at ₩41.64 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> ORION 控股公司的收入部分包括糖果业务₩3.90 万亿，房东业务₩66.56 亿，以及视频业务₩41.64 亿。</p>
</div><p><strong>Dividend Yield:</strong> 3.6%</p>
<div class="lb-trans"><p><strong>股息收益率：</strong> 3.6%</p>
</div><p>ORION Holdings' dividend payments are well-covered by both earnings and cash flows, with a payout ratio of 31.5% and a cash payout ratio of 12.6%. However, the dividends have been volatile over the past decade, showing unreliability despite growth in payouts during this period. Recent earnings reports indicate fluctuating performance, with Q1 2025 net income decreasing compared to the previous year, highlighting potential challenges for maintaining stable dividends.</p>
<div class="lb-trans"><p>ORION 控股的股息支付得到了收益和现金流的良好支持，派息比率为 31.5%，现金派息比率为 12.6%。然而，过去十年股息波动较大，尽管在此期间支付有所增长，但显示出不可靠性。最近的财报显示业绩波动，2025 年第一季度净收入较去年下降，突显出维持稳定股息的潜在挑战。</p>
</div><ul>
<li>Click here to discover the nuances of ORION Holdings with our detailed analytical dividend report.</li>
<li>Our valuation report here indicates ORION Holdings may be undervalued.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击这里了解 ORION 控股的细微差别，查看我们的详细分析股息报告。</li>
<li>我们的估值报告显示 ORION 控股可能被低估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend" alt="" original-src="https://images.simplywall.st/company/c3bf4584-2fd0-43d9-ad83-cf27eac49f1f/chart/historic-dividend"/></p>
<p>KOSE:A001800 Dividend History as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 KOSE:A001800 股息历史</p>
</div><h2>Guilin Sanjin Pharmaceutical (SZSE:002275)</h2>
<div class="lb-trans"><h2>桂林三金药业 (SZSE:002275)</h2>
</div><p><strong>Simply Wall St Dividend Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 股息评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Guilin Sanjin Pharmaceutical Co., Ltd. focuses on the research, production, and sale of traditional Chinese and natural medicines in China, with a market cap of CN¥8.62 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 桂林三金药业有限公司专注于中国传统中药和天然药物的研究、生产和销售，市值为 CN¥86.2 亿。</p>
</div><p><strong>Operations:</strong> Guilin Sanjin Pharmaceutical Co., Ltd. generates its revenue primarily through the research, production, and sale of traditional Chinese and natural medicines in China.</p>
<div class="lb-trans"><p><strong>运营：</strong> 桂林三金药业有限公司主要通过研究、生产和销售中国传统中药和天然药物来产生收入。</p>
</div><p><strong>Dividend Yield:</strong> 3.7%</p>
<div class="lb-trans"><p><strong>股息收益率：</strong> 3.7%</p>
</div><p>Guilin Sanjin Pharmaceutical's dividend is well-covered by earnings and cash flows, with payout ratios of 66.6% and 67.9%, respectively. Despite being among the top dividend payers in China, its track record has been unstable over the past decade, with no growth in payments. Recent approval of a CNY 3.50 per 10 shares dividend highlights commitment to returns despite past volatility and large one-off items affecting financial results.</p>
<div class="lb-trans"><p>桂林三金药业的股息得到了收益和现金流的良好支持，派息比率分别为 66.6% 和 67.9%。尽管在中国是顶级股息支付者之一，但其过去十年的记录不稳定，支付没有增长。最近批准的每 10 股派发 CNY 3.50 的股息突显了尽管过去波动和大额一次性项目影响财务结果，仍然致力于回报。</p>
</div><ul>
<li>Navigate through the intricacies of Guilin Sanjin Pharmaceutical with our comprehensive dividend report here.</li>
<li>Our expertly prepared valuation report Guilin Sanjin Pharmaceutical implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过我们的综合股息报告了解桂林三金药业的复杂性。</li>
<li>我们精心准备的桂林三金药业估值报告暗示其股价可能低于预期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend" alt="" original-src="https://images.simplywall.st/company/16ff3920-688e-4213-bd0a-3d3ffb2f4211/chart/historic-dividend"/></p>
<p>SZSE:002275 Dividend History as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 SZSE:002275 股息历史</p>
</div><h2>Qingdao Baheal Medical (SZSE:301015)</h2>
<div class="lb-trans"><h2>青岛百合医疗 (SZSE:301015)</h2>
</div><p><strong>Simply Wall St Dividend Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 股息评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Qingdao Baheal Medical INC. is involved in the research, development, production, and sale of pharmaceutical products and has a market cap of CN¥9.84 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 青岛百合医疗有限公司从事药品的研究、开发、生产和销售，市值为 CN¥98.4 亿。</p>
</div><p><strong>Operations:</strong> Qingdao Baheal Medical INC. generates its revenue through the research, development, production, and sale of pharmaceutical products.</p>
<div class="lb-trans"><p><strong>运营：</strong> 青岛百合医疗有限公司通过药品的研究、开发、生产和销售来产生收入。</p>
</div><p><strong>Dividend Yield:</strong> 3.8%</p>
<div class="lb-trans"><p><strong>股息收益率：</strong> 3.8%</p>
</div><p>Qingdao Baheal Medical's dividend payments are well-supported by earnings and cash flows, with payout ratios of 67.6% and 68.2%, respectively. Although the company has only paid dividends for three years, its CNY 7.62 per 10 shares dividend reflects a stable commitment to shareholders, placing it among the top dividend payers in China. Despite recent earnings pressure with net income declining to CNY 85 million in Q1 2025, dividends remain sustainable due to strong coverage metrics.</p>
<div class="lb-trans"><p>青岛百合医疗的股息支付得到了收益和现金流的良好支持，派息比率分别为 67.6% 和 68.2%。尽管该公司仅支付了三年的股息，但每 10 股派发 CNY 7.62 的股息反映了对股东的稳定承诺，使其成为中国顶级股息支付者之一。尽管最近的收益压力使 2025 年第一季度净收入下降至 CNY 8500 万，但由于强劲的覆盖指标，股息仍然可持续。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Qingdao Baheal Medical's dividend report.</li>
<li>The valuation report we've compiled suggests that Qingdao Baheal Medical's current price could be quite moderate.</li>
</ul>
<div class="lb-trans"><ul>
<li>点击探索我们在青岛百合医疗股息报告中的详细发现。</li>
<li>我们编制的估值报告表明青岛百合医疗的当前价格可能相当适中。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend" alt="" original-src="https://images.simplywall.st/company/c1564707-10a2-4496-b403-a7ae4c73555b/chart/historic-dividend"/></p>
<p>SZSE:301015 Dividend History as at Jun 2025</p>
<div class="lb-trans"><p>截至 2025 年 6 月的 SZSE:301015 股息历史</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>将想法转化为行动</h2>
</div><ul>
<li>Navigate through the entire inventory of 1552 Top Global Dividend Stocks here.</li>
<li>Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.</li>
<li>Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里浏览 1552 只全球顶级股息股票的完整清单。</li>
<li>已经拥有这些公司？将您的投资组合链接到 Simply Wall St，并获取任何新警告信号的提醒。</li>
<li>Simply Wall St 是您解锁全球市场趋势的关键，是一款面向前瞻性投资者的免费用户友好应用。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>准备好不同的方法了吗？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未获得显著分析师关注的高表现小型公司。</li>
<li>用显示强劲增长潜力的公司来充实您的投资组合，得到分析师和管理层的乐观展望支持。</li>
<li>寻找现金流潜力良好但交易价格低于其公允价值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇来自 Simply Wall St 的文章具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章并不意图作为财务建议。</strong> 它不构成购买或出售任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>

2025 年 6 月值得关注的全球股息股票